Ampreloxetine

Ampreloxetine is a selective norepinephrine reuptake inhibitor which is under development for the treatment of symptomatic neurogenic orthostatic hypotension.
It shows high affinity for both the norepinephrine transporter and the serotonin transporter, with 4-fold selectivity for the NET over the SERT, and is thought to act as a dual serotonin–norepinephrine reuptake inhibitor at higher doses.
As of November 2023, ampreloxetine is in phase 3 clinical trials for NOH. The drug was also under development for the treatment of attention deficit hyperactivity disorder and fibromyalgia, but development for these uses was discontinued.